Achilles Therapeutics plc (NASDAQ:ACHL – Get Free Report) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 37,800 shares, a decrease of 49.5% from the March 31st total of 74,800 shares. Based on an average daily trading volume, of 770,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the company are short sold.
Institutional Trading of Achilles Therapeutics
An institutional investor recently bought a new position in Achilles Therapeutics stock. Vestal Point Capital LP purchased a new position in Achilles Therapeutics plc (NASDAQ:ACHL – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 108,083 shares of the company’s stock, valued at approximately $96,000. Vestal Point Capital LP owned 0.27% of Achilles Therapeutics at the end of the most recent quarter. 56.38% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
ACHL has been the subject of a number of analyst reports. Chardan Capital reduced their target price on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, April 5th. Piper Sandler reissued a “neutral” rating and set a $2.00 target price (down from $8.00) on shares of Achilles Therapeutics in a research note on Friday, April 5th.
Achilles Therapeutics Stock Down 1.9 %
Achilles Therapeutics stock opened at $0.76 on Friday. The firm has a 50-day moving average price of $1.11 and a two-hundred day moving average price of $0.96. The firm has a market capitalization of $30.31 million, a price-to-earnings ratio of -0.44 and a beta of 1.09. Achilles Therapeutics has a 52-week low of $0.74 and a 52-week high of $1.76.
Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) last posted its earnings results on Thursday, April 4th. The company reported ($0.46) earnings per share (EPS) for the quarter. Research analysts expect that Achilles Therapeutics will post -1.34 earnings per share for the current year.
Achilles Therapeutics Company Profile
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Featured Stories
- Five stocks we like better than Achilles Therapeutics
- The How and Why of Investing in Gold Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Investors Need to Know to Beat the Market
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.